These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Long-term safety, tolerability, and efficacy of magnesium valproate versus sodium valproate in acute seizures. Peng X; Yan Y; Chen R; Wang X; Xu X Curr Med Res Opin; 2020 Feb; 36(2):271-276. PubMed ID: 31775535 [No Abstract] [Full Text] [Related]
16. Effects of sodium valproate in 100 children with special reference to weight. Egger J; Brett EM Br Med J (Clin Res Ed); 1981 Aug; 283(6291):577-81. PubMed ID: 6790086 [TBL] [Abstract][Full Text] [Related]
17. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Brigo F; Igwe SC Cochrane Database Syst Rev; 2017 Feb; 2(2):CD003032. PubMed ID: 28195639 [TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity and valproate therapy. Betrosian A; Frantzeskaki F Intern Med J; 2006 Nov; 36(11):752-4. PubMed ID: 17040368 [No Abstract] [Full Text] [Related]
19. Unusual cutaneous reaction with sodium valproate. Roy S; Goel D Neurol India; 2009; 57(2):216-7. PubMed ID: 19439862 [No Abstract] [Full Text] [Related]
20. Sodium valproate-induced Fanconi type proximal renal tubular acidosis. Knights M; Thekkekkara T; Morris A; Finlay E BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26823359 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]